ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

repaglinide

Also written as “Repaglinide”, “repaglinide and metformin combination tablet” and “Repaglinide/Metformin combination, Repaglinide, Metformin”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Overweight · Gastrointestinal Stromal Tumors · Gout, led by 4 companies.

Drug pageRepaglinide: every studyAll 41 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jun 25, 200718 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novo Nordisk130 open or runningphase 4since Jun 25, 2007Jun 25, 2007none ahead
Eli Lillyits history only30 open or runningphase 1since Jul 20, 2022Jul 20, 2022none ahead
Dalim BioTechits history only10 open or runningphase 1since Jan 29, 2013Jan 29, 2013none ahead
Merckits history only10 open or runningphase 4since Oct 16, 2012Oct 16, 2012none ahead

Also a collaborator on its studies: Basilea Pharmaceutica International.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Novo Nordisk only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jun 25, 2007First study: phase 4 study in Diabetes MellitusFirst studyNCT00491725 · 187 enrolled · China
  2. Dec 4, 20072 phase 4 studies in Diabetes MellitusNCT00568984, NCT00568074
  3. Nov 26, 2008Phase 4 study in Diabetes MellitusNCT00799448 · 40 enrolled · Greece
  4. Aug 13, 2009Phase 1 study in Diabetes MellitusNCT00959101 · 42 enrolled · China
  5. Nov 26, 2009Phase 4 study in Diabetes MellitusNCT01022762 · 440 enrolled · China
  6. Dec 8, 20112 phase 1 studies in Diabetes MellitusNCT01490658, NCT01489644
  7. Mar 22, 2012Phase 3 study in Diabetes MellitusNCT01562561 · 213 enrolled · Hong Kong, Malaysia, Philippines and more
  8. May 16, 2012Phase 4 study in Diabetes MellitusNCT01605773 · 51 enrolled · United States
  9. Oct 1, 20123 phase 4 studies in Diabetes MellitusNCT01698931, NCT01720303, NCT01720290

TargetBeta

“Sulfonylurea receptor 1, Kir6.2 blocker”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
mitiglinideruleKissei Pharmaceuticalphase 49

Studies

All 13 Novo Nordisk leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01720303Diabetes Mellitus · China4CompletedApr 10, 2003159
NCT01720290Diabetes Mellitus · China4CompletedFeb 25, 2003150
NCT01698931Diabetes Mellitus · Italy4CompletedMar 6, 20039
NCT01605773Diabetes Mellitus · United States4CompletedMar 13, 200351
NCT01562561Diabetes Mellitus · Hong Kong, Malaysia, Philippines and more3CompletedDec 20, 2002213
NCT01490658Diabetes Mellitus · United States1CompletedAug 200693
NCT01489644Diabetes Mellitus · United States1CompletedJul 200662
NCT01022762Diabetes Mellitus · China4CompletedNov 2010440
NCT00959101Diabetes Mellitus · China1CompletedOct 200942
NCT00799448Diabetes Mellitus · Greece4TerminatedSep 20, 200440
NCT00568984Diabetes Mellitus · China, Malaysia, Philippines and more4CompletedNov 10, 2003324
NCT00568074Diabetes Mellitus · China4CompletedSep 2, 2004131
NCT00491725Diabetes Mellitus · China4CompletedJun 2006187

How it is read

Names in the registry

  • “Repaglinide”, 15 entries
  • “repaglinide”, 13 entries
  • “repaglinide and metformin combination tablet”, 2 entries
  • “Repaglinide/Metformin combination, Repaglinide, Metformin”, 2 entries
  • “repaglinide 0.5 mg tablet”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.